Sonoma Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Sonoma Pharmaceuticals, Inc. announced its fiscal year 2026 results, highlighting a 37% increase in total revenue to $19.5 million, driven by strong performance in the United States and international markets.
NASDAQ
Sonoma Pharmaceuticals, Inc. reported a net loss of $3.457 million for fiscal year 2025, despite a 12% increase in total revenue to $14.288 million, raising substantial doubt about its ability to continue as a going concern.
NASDAQ
10-K: Sonoma Pharmaceuticals Reports Fiscal Year 2024 Results, Cites Ongoing Losses and Need for Capital
Sonoma Pharmaceuticals' 10-K filing reveals continued losses, a need for additional capital, and ongoing efforts to expand product reach and reduce costs.